EP1789432A1 - Methansulfonatsalze von abirateron-3-estern und wiederherstellung von salzen von abirateron-3-estern durch auflösung in methyl-tert-butyl-ether - Google Patents
Methansulfonatsalze von abirateron-3-estern und wiederherstellung von salzen von abirateron-3-estern durch auflösung in methyl-tert-butyl-etherInfo
- Publication number
- EP1789432A1 EP1789432A1 EP05775781A EP05775781A EP1789432A1 EP 1789432 A1 EP1789432 A1 EP 1789432A1 EP 05775781 A EP05775781 A EP 05775781A EP 05775781 A EP05775781 A EP 05775781A EP 1789432 A1 EP1789432 A1 EP 1789432A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- salt
- reaction
- abiraterone
- esters
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 title claims abstract description 47
- 150000003839 salts Chemical class 0.000 title claims abstract description 42
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 title claims abstract description 24
- 238000011084 recovery Methods 0.000 title description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- 239000002253 acid Substances 0.000 claims abstract description 22
- 229940098779 methanesulfonic acid Drugs 0.000 claims abstract description 9
- 239000002904 solvent Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 10
- 125000002252 acyl group Chemical group 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 6
- 239000012458 free base Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 125000004423 acyloxy group Chemical group 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- UXLDFTUCNFDMOT-UHFFFAOYSA-N 2,3-dihydroxy-2-(2-methylbenzoyl)butanedioic acid Chemical compound CC1=CC=CC=C1C(=O)C(O)(C(O)C(O)=O)C(O)=O UXLDFTUCNFDMOT-UHFFFAOYSA-N 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 abstract description 6
- 238000006243 chemical reaction Methods 0.000 description 64
- 239000002585 base Substances 0.000 description 47
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 44
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 230000015572 biosynthetic process Effects 0.000 description 31
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 28
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 26
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 description 23
- 229960004103 abiraterone acetate Drugs 0.000 description 23
- 239000000047 product Substances 0.000 description 23
- 239000000243 solution Substances 0.000 description 22
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical group FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 20
- 150000002576 ketones Chemical class 0.000 description 17
- 235000019439 ethyl acetate Nutrition 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 11
- 238000000354 decomposition reaction Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 9
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 238000006069 Suzuki reaction reaction Methods 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- HVHZEKKZMFRULH-UHFFFAOYSA-N 2,6-ditert-butyl-4-methylpyridine Chemical compound CC1=CC(C(C)(C)C)=NC(C(C)(C)C)=C1 HVHZEKKZMFRULH-UHFFFAOYSA-N 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 5
- -1 enol triflate Chemical class 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000004570 mortar (masonry) Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000005530 alkylenedioxy group Chemical group 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000012973 diazabicyclooctane Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 3
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 229960000853 abiraterone Drugs 0.000 description 2
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- OJKBCQOJVMAHDX-UHFFFAOYSA-N diethyl(pyridin-3-yl)borane Chemical compound CCB(CC)C1=CC=CN=C1 OJKBCQOJVMAHDX-UHFFFAOYSA-N 0.000 description 2
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 150000002895 organic esters Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- QVCUKHQDEZNNOC-UHFFFAOYSA-N 1,2-diazabicyclo[2.2.2]octane Chemical compound C1CC2CCN1NC2 QVCUKHQDEZNNOC-UHFFFAOYSA-N 0.000 description 1
- JILHZKWLEAKYRC-UHFFFAOYSA-N 1-methoxy-2,2-dimethylpropane Chemical compound COCC(C)(C)C JILHZKWLEAKYRC-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001854 Steroid 17-alpha-Hydroxylase Human genes 0.000 description 1
- 108010015330 Steroid 17-alpha-Hydroxylase Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 239000003759 ester based solvent Substances 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- MTWSTCXAJXEKJQ-UHFFFAOYSA-N ethyl acetate;2-methoxy-2-methylpropane Chemical compound CCOC(C)=O.COC(C)(C)C MTWSTCXAJXEKJQ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- GHXZPUGJZVBLGC-UHFFFAOYSA-N iodoethene Chemical compound IC=C GHXZPUGJZVBLGC-UHFFFAOYSA-N 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- NCMZQTLCXHGLOK-ZKHIMWLXSA-N prasterone acetate Chemical compound C([C@@H]12)C[C@]3(C)C(=O)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 NCMZQTLCXHGLOK-ZKHIMWLXSA-N 0.000 description 1
- 229950005326 prasterone acetate Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI200531092T SI1789432T1 (sl) | 2004-08-24 | 2005-08-23 | Metansulfonatne soli abirateron-3-estrov in rekuperiranje soli abirateron-3-estrov iz raztopine v metilterc.-butil etru |
PL05775781T PL1789432T3 (pl) | 2004-08-24 | 2005-08-23 | Sole metanosulfonianowe 3-estrów abirateronu i odzyskiwanie soli 3-estrów abirateronu z roztworu w eterze metylowo-tert-butylowym |
CY20101100867T CY1110800T1 (el) | 2004-08-24 | 2010-09-27 | Μεθανοσουλφονικα αλατα αβιρατερονης-3-εστερων και ανακτηση αλατων αβιρατερονης-3-εστερων απο διαλυμα σε μεθυλο τριτ-βουτυλαιθερα |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60355904P | 2004-08-24 | 2004-08-24 | |
GBGB0418900.7A GB0418900D0 (en) | 2004-08-24 | 2004-08-24 | Novel salt forms |
PCT/GB2005/003282 WO2006021776A1 (en) | 2004-08-24 | 2005-08-23 | Methanesulfonate salts of abiraterone-3-esters and recovery of salts of abirater one-3-esters from solution in methyl tert-butyl ether |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1789432A1 true EP1789432A1 (de) | 2007-05-30 |
EP1789432B1 EP1789432B1 (de) | 2010-06-30 |
Family
ID=33104570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05775781A Active EP1789432B1 (de) | 2004-08-24 | 2005-08-23 | Methansulfonatsalze von abirateron-3-estern und wiederherstellung von salzen von abirateron-3-estern durch auflösung in methyl-tert-butyl-ether |
Country Status (22)
Country | Link |
---|---|
US (5) | US7700766B2 (de) |
EP (1) | EP1789432B1 (de) |
JP (1) | JP5069561B2 (de) |
KR (2) | KR101245727B1 (de) |
CN (2) | CN102863498B (de) |
AT (1) | ATE472553T1 (de) |
AU (1) | AU2005276298C1 (de) |
BR (1) | BRPI0514543A (de) |
CA (1) | CA2576922C (de) |
CY (1) | CY1110800T1 (de) |
DE (1) | DE602005022083D1 (de) |
DK (1) | DK1789432T3 (de) |
ES (1) | ES2345345T3 (de) |
GB (1) | GB0418900D0 (de) |
HK (2) | HK1103091A1 (de) |
MX (1) | MX2007002032A (de) |
NZ (1) | NZ553085A (de) |
PL (1) | PL1789432T3 (de) |
PT (1) | PT1789432E (de) |
SI (1) | SI1789432T1 (de) |
WO (1) | WO2006021776A1 (de) |
ZA (1) | ZA200701533B (de) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013030410A2 (en) | 2011-12-23 | 2013-03-07 | Crystal Pharma, S.A.U. | Synthesis of abiraterone and related compounds |
WO2013053691A1 (en) | 2011-10-10 | 2013-04-18 | Zach System | Process for preparing 17-substituted steroids |
WO2014064032A1 (en) | 2012-10-22 | 2014-05-01 | Olon S.P.A. | Process for the purification of abiraterone acetate |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8569275B2 (en) | 2002-08-28 | 2013-10-29 | Harbor Therapeutics, Inc. | Steroids having 7-oxgen and 17-heteroaryl substitution |
GB0418900D0 (en) * | 2004-08-24 | 2004-09-29 | Btg Int Ltd | Novel salt forms |
EP1781683B1 (de) * | 2004-08-24 | 2011-11-16 | BTG International Limited | Verfahren zur herstellung von 17-vinyl-triflaten als intermediate |
CN104306977A (zh) * | 2006-08-25 | 2015-01-28 | 库伽尔生物科技公司 | 治疗癌症的方法和组合物 |
US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
MY155570A (en) | 2009-06-26 | 2015-10-30 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
WO2012035078A1 (en) | 2010-09-16 | 2012-03-22 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
CN102558274B (zh) * | 2010-12-08 | 2014-10-15 | 深圳万乐药业有限公司 | 一种适合工业化生产醋酸阿比特龙的合成方法 |
CN102030798B (zh) * | 2010-12-17 | 2012-10-17 | 深圳万乐药业有限公司 | 一种醋酸阿比特龙的纯化方法 |
EP2702052B1 (de) | 2011-04-28 | 2017-10-18 | Novartis AG | 17a-hydroxylase/c17,20-lyase hemmer |
CN103172690B (zh) * | 2011-12-23 | 2016-08-24 | 重庆医药工业研究院有限责任公司 | 醋酸阿比特龙及其中间体的制备方法 |
CN103193849B (zh) * | 2012-01-04 | 2016-05-04 | 连云港润众制药有限公司 | 一种高纯度醋酸阿比特龙的制备方法 |
CN103254265B (zh) | 2012-02-21 | 2016-07-13 | 上海希迈医药科技有限公司 | 醋酸阿比特龙三氟乙酸盐及其制备方法和应用 |
CN103360458B (zh) * | 2012-03-26 | 2015-05-20 | 信泰制药(苏州)有限公司 | 一种阿比特龙的合成方法 |
CN102731605B (zh) * | 2012-06-19 | 2016-04-13 | 鲁南制药集团股份有限公司 | 一种醋酸阿比特龙的纯化方法 |
CN103665084A (zh) * | 2012-09-04 | 2014-03-26 | 重庆安格龙翔医药科技有限公司 | 一种制备醋酸阿比特龙的方法 |
CN102816200B (zh) * | 2012-09-05 | 2015-04-15 | 中山大学 | 一种醋酸阿比特龙的制备方法 |
CN102816201A (zh) * | 2012-09-25 | 2012-12-12 | 成都伊诺达博医药科技有限公司 | 一种阿比特龙的纯化方法 |
WO2014058785A1 (en) | 2012-10-10 | 2014-04-17 | Novartis Ag | Combination therapy |
WO2014071983A1 (en) | 2012-11-09 | 2014-05-15 | Synthon Bv | Process for making the 17-triflate intermediate of abiraterone-3-acetate |
WO2014071984A1 (en) | 2012-11-09 | 2014-05-15 | Synthon Bv | Process for making abiraterone-3-acetate |
TWI570131B (zh) * | 2012-11-13 | 2017-02-11 | 賽克系統公司 | 製備17-經取代類固醇之方法 |
WO2014075978A1 (en) | 2012-11-16 | 2014-05-22 | Synthon B.V. | Process for the production of abiraterone-3-acetate involving an enol trliflation reaction in the presence of an alkoxy-pyridine compound |
CN103059091B (zh) * | 2012-11-22 | 2017-04-19 | 常州靶点医药科技有限公司 | 一种避免重金属残留的醋酸阿比特龙的制备方法 |
WO2014121033A1 (en) | 2013-02-04 | 2014-08-07 | Fl Therapeutics Llc | Soluble complexes of drug analogs and albumin |
ES2612780T3 (es) | 2013-04-19 | 2017-05-18 | Zach System | Proceso para producir una forma sólida de acetato de abiraterona |
CN103242410B (zh) * | 2013-05-09 | 2015-08-26 | 苏州明锐医药科技有限公司 | 醋酸阿比特龙的制备方法 |
EP3013844A4 (de) * | 2013-06-24 | 2017-03-01 | Sun Pharmaceutical Industries LTD | Verfahren zur herstellung von abirateronacetat |
KR20160024930A (ko) * | 2013-06-28 | 2016-03-07 | 시노팜 타이완 리미티드 | 아비라테론 및 이의 중간체의 제조를 위한 방법 |
CZ306623B6 (cs) * | 2013-07-04 | 2017-04-05 | Zentiva, K.S. | Soli abirateronu acetátu |
EP3080141A1 (de) | 2013-12-12 | 2016-10-19 | Basf Se | Feste form von abirateronacetat |
WO2015114518A2 (en) | 2014-01-28 | 2015-08-06 | Olon S.P.A. | Procedure for the preparation of abiraterone acetate and intermediates thereof |
CN103965282B (zh) | 2014-04-21 | 2016-01-20 | 武汉百科药物开发有限公司 | 一种醋酸阿比特龙的制备方法 |
US9315541B2 (en) * | 2014-05-20 | 2016-04-19 | Olon S.P.A. | Process for the preparation of unsaturated trifluoromethanesulfonate steroid derivatives |
CN105294806A (zh) * | 2014-06-13 | 2016-02-03 | 江苏希迪制药有限公司 | 一种制备醋酸阿比特龙中间体的方法 |
US9937259B2 (en) | 2014-06-27 | 2018-04-10 | Zhuhai Beihai Biotech Co., Ltd. | Abiraterone derivatives and non-covalent complexes with albumin |
WO2016065139A1 (en) | 2014-10-24 | 2016-04-28 | Fl Therapeutics Llc | 3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin |
CN104447934B (zh) * | 2014-12-08 | 2017-03-15 | 深圳科兴生物工程有限公司 | 一种醋酸阿比特龙的纯化方法 |
EP3824908A1 (de) | 2015-04-10 | 2021-05-26 | Capsugel Belgium NV | Abirateron-acetat-lipidformulierungen |
WO2018071544A1 (en) | 2016-10-11 | 2018-04-19 | Zhuhai Beihai Biotech Co., Ltd. | Abiraterone derivative and formulations thereof |
CN108586561B (zh) * | 2018-04-03 | 2020-08-04 | 科兴生物制药股份有限公司 | 一种制备醋酸阿比特龙的方法 |
MX2021010553A (es) | 2019-03-06 | 2021-12-15 | Propella Therapeutics Inc | Profarmacos de abiraterona. |
CN112812147A (zh) * | 2019-11-15 | 2021-05-18 | 江苏佳尔科药业集团股份有限公司 | 一种醋酸阿比特龙的合成方法及其中间体 |
EP4291159A1 (de) | 2021-02-15 | 2023-12-20 | Propella Therapeutics, Inc. | Abirateron-prodrugs |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5604213A (en) * | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
CA2132449C (en) | 1992-03-31 | 2002-09-10 | Susan E. Barrie | 17 - substituted steroids useful in cancer treatment |
CA2170286C (en) | 1993-09-30 | 2005-04-05 | Gerard Andrew Potter | Synthesis of 17-(3-pyridyl) steroids |
GB0418900D0 (en) * | 2004-08-24 | 2004-09-29 | Btg Int Ltd | Novel salt forms |
-
2004
- 2004-08-24 GB GBGB0418900.7A patent/GB0418900D0/en not_active Ceased
-
2005
- 2005-08-23 PL PL05775781T patent/PL1789432T3/pl unknown
- 2005-08-23 WO PCT/GB2005/003282 patent/WO2006021776A1/en active Application Filing
- 2005-08-23 JP JP2007528970A patent/JP5069561B2/ja active Active
- 2005-08-23 KR KR1020077004205A patent/KR101245727B1/ko active IP Right Grant
- 2005-08-23 EP EP05775781A patent/EP1789432B1/de active Active
- 2005-08-23 US US11/660,869 patent/US7700766B2/en active Active
- 2005-08-23 DK DK05775781.7T patent/DK1789432T3/da active
- 2005-08-23 PT PT05775781T patent/PT1789432E/pt unknown
- 2005-08-23 NZ NZ553085A patent/NZ553085A/en unknown
- 2005-08-23 CA CA2576922A patent/CA2576922C/en active Active
- 2005-08-23 CN CN201210299567.4A patent/CN102863498B/zh active Active
- 2005-08-23 ES ES05775781T patent/ES2345345T3/es active Active
- 2005-08-23 SI SI200531092T patent/SI1789432T1/sl unknown
- 2005-08-23 AU AU2005276298A patent/AU2005276298C1/en active Active
- 2005-08-23 AT AT05775781T patent/ATE472553T1/de active
- 2005-08-23 CN CN2005800360449A patent/CN101044155B/zh active Active
- 2005-08-23 DE DE602005022083T patent/DE602005022083D1/de active Active
- 2005-08-23 KR KR1020127031465A patent/KR101358661B1/ko active IP Right Grant
- 2005-08-23 ZA ZA200701533A patent/ZA200701533B/xx unknown
- 2005-08-23 MX MX2007002032A patent/MX2007002032A/es active IP Right Grant
- 2005-08-23 BR BRPI0514543-0A patent/BRPI0514543A/pt not_active Application Discontinuation
-
2007
- 2007-10-18 HK HK07111340.7A patent/HK1103091A1/xx unknown
-
2010
- 2010-02-04 US US12/656,581 patent/US8076474B2/en active Active
- 2010-09-27 CY CY20101100867T patent/CY1110800T1/el unknown
-
2011
- 2011-11-02 US US13/317,997 patent/US8338588B2/en active Active
-
2012
- 2012-11-26 US US13/685,004 patent/US20130090468A1/en not_active Abandoned
-
2013
- 2013-07-09 HK HK13108036.4A patent/HK1180694A1/xx unknown
-
2015
- 2015-07-23 US US14/807,086 patent/US20150329585A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2006021776A1 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013053691A1 (en) | 2011-10-10 | 2013-04-18 | Zach System | Process for preparing 17-substituted steroids |
US9353145B2 (en) | 2011-10-10 | 2016-05-31 | Zach System | Process for preparing 17-substituted steroids |
WO2013030410A2 (en) | 2011-12-23 | 2013-03-07 | Crystal Pharma, S.A.U. | Synthesis of abiraterone and related compounds |
EP2607371A1 (de) | 2011-12-23 | 2013-06-26 | Crystal Pharma, S.A.U. | Verfahren zur Herstellung von Abirateron und verwandten Verbindungen |
WO2014064032A1 (en) | 2012-10-22 | 2014-05-01 | Olon S.P.A. | Process for the purification of abiraterone acetate |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005276298B2 (en) | Methanesulfonate salts of abiraterone-3-esters and recovery of salts of abirater one-3-esters from solution in methyl tert-butyl ether | |
DK2428519T3 (en) | A composition for the preparation of 17-vinyl triflates as intermediates | |
EP2766381B1 (de) | Verfahren zur herstellung von 17-substituierten steroiden | |
JP5639895B2 (ja) | 立体選択的還元方法 | |
EP2890705A1 (de) | Verfahren zur herstellung von abirateron oder abirateronacetat | |
PL173451B1 (pl) | Nowy sposób wytwarzania pochodnych pregnanu |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20070320 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1103091 Country of ref document: HK |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BTG INTERNATIONAL LIMITED |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: KIRKER & CIE S.A. |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20100729 |
|
REF | Corresponds to: |
Ref document number: 602005022083 Country of ref document: DE Date of ref document: 20100812 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2345345 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20100402034 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: RO Ref legal event code: EPE |
|
REG | Reference to a national code |
Ref country code: PL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: EE Ref legal event code: FG4A Ref document number: E004733 Country of ref document: EE Effective date: 20100915 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1103091 Country of ref document: HK |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: T3 Ref document number: E 8027 Country of ref document: SK |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E008763 Country of ref document: HU |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20110331 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602005022083 Country of ref document: DE Effective date: 20110330 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20230721 Year of fee payment: 19 Ref country code: LU Payment date: 20230720 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20230727 Year of fee payment: 19 Ref country code: RO Payment date: 20230821 Year of fee payment: 19 Ref country code: MC Payment date: 20230724 Year of fee payment: 19 Ref country code: IT Payment date: 20230720 Year of fee payment: 19 Ref country code: IE Payment date: 20230724 Year of fee payment: 19 Ref country code: GB Payment date: 20230720 Year of fee payment: 19 Ref country code: FI Payment date: 20230720 Year of fee payment: 19 Ref country code: ES Payment date: 20230901 Year of fee payment: 19 Ref country code: EE Payment date: 20230721 Year of fee payment: 19 Ref country code: CZ Payment date: 20230725 Year of fee payment: 19 Ref country code: CY Payment date: 20230721 Year of fee payment: 19 Ref country code: CH Payment date: 20230902 Year of fee payment: 19 Ref country code: BG Payment date: 20230803 Year of fee payment: 19 Ref country code: AT Payment date: 20230721 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SK Payment date: 20230727 Year of fee payment: 19 Ref country code: SI Payment date: 20230725 Year of fee payment: 19 Ref country code: SE Payment date: 20230720 Year of fee payment: 19 Ref country code: PT Payment date: 20230724 Year of fee payment: 19 Ref country code: PL Payment date: 20230720 Year of fee payment: 19 Ref country code: IS Payment date: 20230720 Year of fee payment: 19 Ref country code: HU Payment date: 20230803 Year of fee payment: 19 Ref country code: GR Payment date: 20230721 Year of fee payment: 19 Ref country code: FR Payment date: 20230720 Year of fee payment: 19 Ref country code: DK Payment date: 20230721 Year of fee payment: 19 Ref country code: DE Payment date: 20230720 Year of fee payment: 19 Ref country code: BE Payment date: 20230720 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LV Payment date: 20230720 Year of fee payment: 19 Ref country code: LT Payment date: 20230720 Year of fee payment: 19 |